Progress in Neuro-Psychopharmacology & Biological Psychiatry

An International Research and Review Journal

Contents, Author Index and Subject Index

Volume 8

L.
84

Pergamon Press

Oxford • New York • Frankfurt

Editor-in-Chief

C. Radouco-Thomas

Laval University Medical School
Quebec, Canada

Executive Editorial Board

T. A. BAN, *Nashville*
H. BARRY III, *Pittsburgh*
F. E. BLOOM, *La Jolla*
M. C. BRAUDE, *Rockville*
W. E. BUNNEY JR., *Irvine*
A. CARLSSON, *Göteborg*
J. COYLE, *Baltimore*
P. DENIKER, *Paris*
J. ELKES, *Baltimore*
D. X. FREEDMAN, *Chicago*
E. GERSHON, *Bethesda*
J. GLOWINSKI, *Paris*
H. HIPPIUS, *Münich*
L. E. HOLLISTER, *Palo Alto*
O. HORNYKIEWICZ, *Vienna*
A. G. KARCZMAR, *Chicago*
P. KIEHOLZ, *Basle*
H. LAL, *Kingston, USA*
A. A. LEEDS, *Rockville*
H. E. LEHMANN, *Montreal*
G. M. LING, *Vienna*
M. LINNOILA, *Bethesda*
J. MENDLEWICZ, *Brussels*
P. V. MOROZOV, *Geneva*
D. L. MURPHY, *Bethesda*
R. M. POST, *Bethesda*
G. RACAGNI, *Milan*
S. RADOUCO-THOMAS, *Quebec*
O. J. RAFAELSEN, *Copenhagen*
N. SARTORIUS, *Geneva*
S. H. SNYDER, *Baltimore*
F. SULSER, *Nashville*
H. M. VAN PRAAG, *New York*
R. J. WYATT, *Washington*

Progress in Neuro-Psychopharmacology & Biological Psychiatry
An International Research, Review and News Journal

Editors-in-Chief: C. Radouco-Thomas and F. Garcin
Associate Editors: Denise B.-Lacroix and S. Chawla
Mailing Address: *Editorial Office, Progress in Neuro-Psychopharmacology & Biological Psychiatry, Lab. of Neuro-Psychopharmacol./RADA Unit, Laval University Medical School, Quebec, Canada, G1K 7P4.*

Executive Editorial Board

T. A. BAN
Vanderbilt University, Nashville
H. BARRY III
University of Pittsburgh, Pittsburgh
F. E. BLOOM
Scripps Clinic, La Jolla, Cal.
M. C. BRAUDE
National Institute on Drug Abuse, Rockville
W. E. BUNNEY JR.
University of California, Irvine
A. CARLSSON
University of Göteborg, Göteborg
J. COYLE
Johns Hopkins University, Baltimore
P. DENIKER
Hôpital Ste-Anne, Paris
J. ELKES
Johns Hopkins University, Baltimore
D. X. FREEDMAN
University of Chicago, Chicago
E. GERSHON
NIMH, Bethesda, Maryland
J. GLOWINSKI
Collège de France, Paris
H. HIPPIUS
University of Münich, FRG
L. E. HOLLISTER
Veterans Administration Hospital, Palo Alto
O. HORNYKIEWICZ
Institute of Biochemical Pharmacology, Vienna
A. G. KARCZMAR
Loyola University, Chicago
P. KIELHOLZ
University of Basle, Basle
H. LAL
Kingston, USA
A. A. LEEDS
National Institute of Mental Health, Rockville
H. E. LEHMANN
McGill University, Montreal
G. M. LING
United Nations, Narcotic Division, Vienna
M. LINNOILA
NIAAA, Bethesda
J. MENDLEWICZ
University of Brussels, Brussels
P. V. MOROZOV
WHO, Geneva, Switzerland
D. L. MURPHY
NIMH, Bethesda
R. M. POST
NIMH, Bethesda
G. RACAGNI
Institute of Pharmacology, Milan
S. RADOUCO-THOMAS
Laval University Medical School, Quebec
O. J. RAFAELSEN
Psychochemistry Institute, Copenhagen
N. SARTORIUS
WHO, Geneva, Switzerland
S. H. SNYDER
Johns Hopkins University, Baltimore
F. SULSER
Vanderbilt University, Nashville
H. M. VAN PRAAG
Albert Einstein College of Medicine, New York
R. J. WYATT
NIMH, Washington, D.C.

Publishing, Subscription and Advertising Offices: Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW. (Oxford 64881; Telex 83177).
Address for subscription enquiries in North America: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, U.S.A.
Published bi-monthly. Annual subscription 1985 (including postage and insurance): for Libraries, Research Establishments and all other multiple-reader institutions – U.S. $180.00. Two years 1985/86 – $342.00.
Specially Reduced Rates to Individuals: In the interest of maximizing the dissemination of the research results published in this important journal we have established a two-tier price structure. Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of U.S. $60.00 per annum.
Microform Subscriptions and Back Issues: Back issues of all previously published volumes will be available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Copyright © 1985 Pergamon Press Ltd.
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organizations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise without permission in writing from the copyright holder.

Photocopying information for users in the U.S.A.
The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $0.50 per page should be forwarded directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon Office.

The Item-Fee Code for this publication is: 0278 – 5846/84 $0.00 + .50.

HEADINGTON HILL HALL
OXFORD OX3 0BW, ENGLAND

PERGAMON PRESS

MAXWELL HOUSE, FAIRVIEW PARK
ELMSFORD, NEW YORK 10523, USA

CONTENTS

Volume 8. No. 1

Editorial advisory board

Organization of the journal

Critical reviews and theoretical articles

B. E. Golinko — 1 Side effects of dextroamphetamine and methylphenidate in hyperactive children — A brief review

Special Topic:

Proceedings of the regional CINP meeting, Hong Kong

Topic Editor: G. D. Burrows — 9 Introduction

L. Dennerstein, A. Callan, G. Warne, J. Montalto, J. Brown, G. Burrows, A. Fulton and M. Notelovitz — 11 The effects of benzodiazepines on hormones in women with idiopathic hirsutism

S. E. File — 19 Behavioural pharmacology of benzodiazepines

A. Fulton and G. D. Burrows — 33 Benzodiazepine anxiolytic action and affinities for serotonergic and adrenergic receptors

H. Itoh, Y. Fujii, M. Kamisada, K. Kamishima, Y. Koga, Y. Masuda, S. Miura, Y. Nabeta, Y. Nakano, K. Ogita, N. Ohtsuka, F. Saitoh, S. Sakurai, K. Satoh, Y. Suzuki, M. Takamiya, S. Tanoue, M. Tateyama, G. Yagi, S. Yamazumi and H. Yoshida — 39 Recent trend on the prevalence of tardive dyskinesia in Japan

H. Itoh, G. Yagi, M. Tateyama, Y. Fujii, K. Iwamura and K. Ichikawa — 51 Monitoring of haloperidol serum levels and its clinical significance

G. F. S. Johnson and G. E. Hunt — 63 Pharmacokinetics of lithium preparations in patients

G. Kato and T. A. Ban — 71 Neurotransmitters and receptors: Clinical implications

S. Kelwala, T. A. Ban, S. A. Berney and W. H. Wilson — 77 Rapid tranquilization: A comparative study of thiothixene and haloperidol

M. Lader — 85 Benzodiazepine dependence

B. E. Leonard — 97 Pharmacology of new antidepressants

P. Marriott, M. Pansa and A. Hiep — 109 Intervals between long acting neuroleptics: Outcome and re-admission variables

T. R. Norman and G. D. Burrows — 115 Plasma concentrations of benzodiazepines — A review of clinical findings and implications

CONTENTS

Volume 8. No. 1, *continued*

M. O'Connor and J. Grigor — 127 Double blind study comparing the efficacy of zimelidine and amitriptyline in endogenous depression

D. H. Overstreet — 133 Behavioural plasticity and the cholinergic system

W. Z. Potter, F. Karoum and M. Linnoila — 153 Common mechanism of action of biochemically "specific" antidepressants

J. S. Salt and P. V. Taberner — 163 Differential effects of benzodiazepines and amphetamine on exploratory behaviour in weanling rats: An animal model for anxiolytic activity

G. Singer and M. Wallace — 171 Schedule-induced self injection of drugs

J. W. Unwin and P. V. Taberner — 179 Ethanol preference in mice following acute or chronic ethanol administration

News and intercommunications in neuro-psychopharmacology — 185 Biological approaches to mental health: A WHO newsletter

203 Past and forthcoming meetings

207 Book reviews

208 Announcement

Volume 8. No. 2

Editorial advisory board

Organization of the journal

Critical reviews and theoretical articles

M. Williams — 209 Molecular aspects of the action of benzodiazepine and non-benzodiazepine anxiolytics: A hypothetical allosteric model of the benzodiazepine receptor complex

Full-length original papers

Experimental laboratory studies

C. T. Dourish and S. J. Cooper — 249 Effects of piribedil and of *d*-amphetamine on locomotor activity in immature rats

P. L. Goldschmidt, L. Savary and P. Simon — 257 Comparison of the stimulatory effects of eight antiparkinsonian drugs

CONTENTS

Volume 8. No. 2, *continued*

S. M. Jancsàr and B. E. Leonard — 263 Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat

M. D. Schechter — 271 Ethanol and pentobarbital have different behavioral effects in the rat

Clinical studies

N. R. Cutler, D. V. Jeste, C. A. Kaufmann, F. Karoum, H. F. Schran and R. J. Wyatt — 277 Low dose bromocriptine: A study of acute effects in chronic medicated schizophrenics

H. Itoh, G. Yagi, Y. Fujii, K. Iwamura and K. Ichikawa — 285 The relationship between haloperidol blood levels and clinical responses

J. R. Patin, H. B. Hamot and J. M. Singer — 293 Replicated evidence on the construct validity of the SCAG (Sandoz Clinical Assessment-Geriatric) scale

News and intercommunications in neuro-psychopharmacology — 307 Past and forthcoming meetings

Volume 8. No. 3

Editorial advisory board

Organization of the journal

Critical reviews and theoretical articles

L. Valzelli — 311 Reflections on experimental and human pathology of aggression

D. F. Smith — 327 Stereopsychopharmacology: Past, present and future

N. Dafny — 351 Interferon: A candidate as the endogenous substance preventing tolerance and dependence to brain opioids

Full-length original papers

Experimental laboratory studies

M. D. Schechter — 359 Specific antagonism of the behavioral effects of chlordiazepoxide and pentobarbital in the rat

E. Kempf, S. Puglisi-Allegra, S. Cabib, C. Schleef and P. Mandel — 365 Serotonin levels and turnover in different brain areas of isolated aggressive or non-aggressive strains of mice

M. Poncelet, F. Hakkou and P. Simon — 373 Psychopharmacological profile of diphenylhydantoin in mice

CONTENTS

Volume 8. No. 3, *continued*

A. F. Crine — 379 Dose-related influence of arginine-vasopressin on a passive avoidance behavior: Effect of rearing conditions

O. Inoue, T. Tominaga, T. Yamasaki and H. Kinemuchi — 385 A new method for *in vivo* measurement of brain monoamine oxidase activity

Clinical studies

T. M. Itil, G. N. Menon, M. M. Bozak and K. Z. Itil — 397 CNS effects of citalopram, a new serotonin inhibitor antidepressant (a quantitative pharmaco-electroencephalography study)

L. Cantalamessa, A. Catania, A. Silva, A. Orsatti, M. Baldini, G. Mosca, C. Zanussi and C. L. Cazzullo — 411 Gonadotropin response to gonadotropin releasing hormone in acute schizophrenia

N. Watanabe, T. Moroji, K. Tada and N. Aoki — 419 A therapeutic trial of caerulein to a long-term heavy marihuana user with amotivational syndrome

Special Topic:

Animal models of depression: New findings

Topic Editor: N. H. Kalin — 423 Introduction

R. M. Post, S. R. B. Weiss and A. Pert — 425 Differential effects of carbamazepine and lithium on sensitization and kindling

S. F. Maier — 435 Learned helplessness and animal models of depression

J. N. Crawley — 447 Preliminary report of a new rodent separation model of depression

N. H. Kalin and M. Carnes — 459 Biological correlates of attachment bond disruption in humans and nonhuman primates

News and intercommunications in neuro-psychopharmacology — 471 Past and forthcoming meetings

472 Announcement

Volume 8. Nos. 4–6

Editorial advisory board

Organization of the journal

473 Editorial note

CONTENTS

Volume 8, Nos. 4–6, *continued*

Academic address

G. M. Brown, O. Pulido, L. J. Grota and L. P. Niles — 475 *N*-acetylserotonin in the central nervous system

Plenary lecture

B. Hamprecht — 481 Cell cultures as models for studying neural functions

Special topic 1 — **Purines and neurotransmission**

T. D. White — 487 Characteristics of neuronal release of ATP

J. W. Phillis — 495 Adenosine's role in the central actions of the benzodiazepines

C. E. Jahr and T. M. Jessel — 503 ATP excites a subpopulation of rat dorsal horn neurones

Special topic 2 — **Neuropharmacology of cells in cultures**

J. Fowler and S. M. Crain — 507 Hyperexcitability in organotypic mouse hippocampal explants

K. C. Marshall, C. B. Garber and P. G. Finlayson — 515 Noradrenergic actions of Purkinje and locus coeruleus neurons in culture

L. Hertz, I. Schousboe, L. Hertz and A. Schousboe — 521 Receptor expression in primary cultures of neurons or astrocytes

M. G. Murphy — 529 Increasing membrane polyunsaturated fatty-acid content augments cyclic AMP formation and prostaglandin production in NIE-115 neuroblastoma

Special topic 3 — **Lithium therapy: Current issues and concerns**

P. Grof and J. Lane — 539 Lithium: Current issues

E. Grof, P. Grof, G. M. Brown and S. Downie — 541 Lithium effects on neuroendocrine function

G. N. Pandey, E. Dorus, R. C. Casper, P. Janicek and J. M. Davis — 547 Lithium transport in red cells of patients with affective disorders

Special topic 4 — **Mechanism of analgesia**

D. J. Mayer — 557 Analgesia produced by electrical stimulation of the brain

K. H. Jhamandas — 565 Opioid – neurotransmitter interactions: significance in analgesia, tolerance and dependence

R. Quirion — 571 Pain, nociception and spinal opioid receptors

J. Sawynok — 581 GABAergic mechanisms in antinociception

CONTENTS

Volume 8. Nos. 4–6, *continued*

Special topic 5 — **Stress**

E. A. Stone, R. Trullas and J. E. Platt — 587 The effect of acute and chronic administration of desmethylimipramine on responses to stress in rats

R. M. Gorczynski and M. Kennedy — 593 Associative learning and regulation of immune responses

R. M. Zacharko, W. J. Bowers and H. Anisman — 601 Responding for brain stimulation: Stress and desmethylimipramine

Special topic 6 — **Neuropsychopharmacology of phenylethylamine**

P. S. McQuade — 607 Analysis and the effects of some drugs on the metabolism of phenylethylamine and phenylacetic acid

A. J. Greenshaw — 615 β-phenylethylamine and reinforcement

Special topic 7 — **Plasticity and CNS**

M. Wilkinson, W. Jacobson and D. A. Wilkinson — 621 Brain slices in radioligand binding assays: quantification of opiate, benzodiazepine and beta-adrenergic ([^{3}H] CGP-12177) receptors

C. Shaw, M. C. Needler, M. Wilkinson, C. Aoki and M. Cynader — 627 Alterations in receptor number, affinity and laminar distribution in cat visual cortex during the critical period

Special topic 8 — **Limbic systems**

R. E. Adamec, C. Stark-Adamec, J.-M. Saint-Hilaire and K. E. Livingston — 635 Basic science and clinical aspects of procaine HCl as a limbic system excitant

Special topic 9 — **Alzheimer's disease**

J.-C. E. Maire and R. J. Wurtman — 637 Choline production from choline-containing phospholipids: a hypothetical role in Alzheimer's disease and aging

F. J. Huff and S. Corkin — 643 Recent advances in the neuropsychology of Alzheimer's disease

Free communications — **Experimental and clinical original papers**

M. Arato, Z. Rihmer, E. Szadoczky and P. Grof — 649 Dexamethasone suppression test as a predictor of drug treatment response

G. B. Baker, D. F. LeGatt, R. T. Coutts and W. G. Dewhurst — 653 Rat brain concentrations of 5-hydroxytryptamine following acute and chronic administration of MAO-inhibiting antidepressants

G. B. Baker, A. J. Nazarali, R. T. Coutts, R. G. Micetich and T. W. Hall — 657 Brain levels of 5-hydroxytryptamine, tryptamine and 2-phenylethylamine in the rat after administration of *N*-cyanoethyltranylcypromine

H. J. Butter, Y. Lapierre, P. Firestone and A. Blank — 661 Efficacy of ACTH 4-9 analog, methylphenidate, and placebo on attention deficity disorder with hyperkinesis

CONTENTS

Volume 8, Nos. 4–6, *continued*

P. Chiu, G. Rajakumar, S. Chiu, C.-Y. Kwan and R. K. Mishra	665	Differential changes in central serotonin and dopamine receptors in spontaneous hypertensive rats
F. M. Coloma and L. P. Niles	669	*In vitro* effects of melatonin in [^{3}H]muscimol binding in rat brain
G. A. Cottrell, C. Nyakas and B. Bohus	673	The behavioural depression of hippocampal kindled rats is attenuated by subcutaneous and intracerebroventricular naltrexone
T. J. Danielson, G. Torok-Both and R. T. Coutts	677	Effects of chronic phenelzine in the rat: altered tissue weights and metabolism of ^{14}C-phenelzine
H. B. Ferguson and J. G. Simeon	683	Evaluating drug effects on children's cognitive functioning
E. Grof, M. Arato, P. Grof, G. M. Brown, J. Lane and B. Saxena	687	Effects of lithium, nortriptyline and dexamethasone on insulin sensitivity
M. E. Kiely, S. Lal, J. Stratford and R. M. Ford	691	Cyclic GMP in sequential samples of lumbar CSF in man
S. Lal, D. Ackman, J. X. Thavundayil, M. E. Kiely and P. Etienne	695	Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects
R. A. Locock, G. B. Baker, R. T. Coutts and W. G. Dewhurst	701	Displacement of serotonin from binding sites in rat cortex: the effects of biogenic "trace" amines
P. S. McQuade and P. L. Wood	705	The effects of administration of *meta*-tyramine and *para*-tyramine on dopamine and its metabolites in the rat striatum
N. P. V. Nair, D. M. Bloom, G Debonnel, G. Schwartz and S. Mosticyan	711	Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study
N. P. V. Nair, N. Hariharasubramanian and C. Pilapil	715	Circadian rhythm of plasma melatonin in endogenous depression
B. G. Rao and M. G. Murphy	719	Opiate peptide receptors on intact NIE-115 neuroblastoma: radioligand binding properties, intracellular response, and effects of increasing membrane cholesterol
M. R. Peterson and H. A. Robertson	725	Effect of dopaminergic agents on levels of dynorphin$_{1-8}$ in rat striatum
J. Sawynok and C. Dickson	729	D-Baclofen: is it an antagonist at baclofen receptors?
J. Seggie, E. S. Werstiuk, L. Grota, M. Joshi and G. M. Brown	733	Lithium and melatonin in pigmented eye rats: effects of dose and time of day
B. Suranyi-Cadotte, R. Quirion, P. McQuade, N. P. V. Nair, G. Schwartz, S. Mosticyan and P. L. Wood	737	Platelet ^{3}H-imipramine binding: a state-dependent marker in depression
H. Szechtman	743	Timing of yawns induced by a small dose of apomorphine and its alteration by naloxone

CONTENTS

Volume 8, Nos. 4–6, *continued*

R. A. R. Tasker, P. L. Vander Velden and K. Nakatsu	747	Relative cataleptic potency of narcotic analgesics, including 3,6-dibutanoylmorphine and 6-monoacetylmorphine
S. P. Tyrer, A. Walsh, D. E. Edwards, T. P. Berney and D. A. Stephens	751	Factors associated with a good response to lithium in aggressive mentally handicapped subjects
M. W. Warenycia and G. M. McKenzie	757	The role of afferents from the parafascicular-centromedian complex in the excitatory striatal neuronal response to dexamphetamine in freely moving animals
M. W. Warenycia, G. M. McKenzie, M. G. Murphy and J. C. Szerb	761	Bilateral ablation of the corticostriatal projection: behavioral, biochemical and electrophysiological correlates
E. S. Werstiuk, J. Seggie and M. Joshi	765	Lithium in pigmented eye rats: effects of dose and time of day on drinking, body weight, retinal and blood distribution
M. Williams and J. L. Robinson	769	Nicotinic receptors in mammalian brain
P. L. Wood and P. S. McQuade	773	Ciclindole and flucindole: novel tetrahydrocarbozolamine neuroleptics
P. L. Wood, P. Etienne, S. Lal and N. P. V. Nair	779	Benzodiazepines and GABAergic regulation of nigrostriatal neurons: lack of tolerance
P. L. Wood, P. Loo, A. Braunwalder and D. L. Cheney	785	*In vitro* characterization of agonist, antagonist, inverse agonist and agonist/antagonist benzodiazepines
P. L. Wood, P. S. McQuade and N. P. V. Nair	789	GABAergic and opioid regulation of the substantia nigra innominata-cortical cholinergic pathway in the rat

AUTHOR INDEX

Ackman, D. 695
Adamec, R. E. 635
Anisman, H. 601
Aoki, C. 627
Aoki, N. 419
Arato, M. 649, 687

Baker, G. B. 653, 657, 701
Baldini, M. 411
Ban, T. A. 71, 77
Berney, S. A. 77
Berney, T. P. 751
Blank, A. 661
Bloom, D. M. 711
Bohus, B. 673
Bowers, W. J. 601
Bozak, M. M. 397
Braunwelder, A. 785
Brown, G. M. 475, 541, 687, 733
Brown, J. 11
Burrows, G. D. 9, 11, 33, 115
Butter, H. J. 661

Cabib, S. 365
Callan, A. 11
Cantalamessa, L. 411
Carnes, M. 459
Casper, R. C. 547
Catania, A. 411
Cazzullo, C. L. 411
Cheney, D. L. 785
Chiu, P. 665
Chiu, S. 665
Coloma, F. M. 669
Cooper, S. J. 249
Corkin, S. 643
Cottrell, G. A. 673
Coutts, R. T. 653, 657, 677, 701
Crain, S. M. 507
Crawley, J. N. 447
Crine A. F. 379
Cutler, N. R. 277
Cynader, M. 627

Dafny, N. 351
Danielson, T. J. 677
Davis, J. M. 547
Debonnel, G. 711
Dennerstein, L. 11
Dewhurst, W. G. 653, 701
Dickson, C. 729
Dourish, C. T. 249
Dorus, E. 547
Downie, S. 541

Edwards, D. E. 751
Etienne, P. 695,779

Ferguson, H. B. 683
File, S. E. 19
Finlayson, P. G. 515
Firestone, P. 661
Ford, R. M. 691
Fowler, J. 507
Fujii, Y. 39, 51, 285
Fulton, A. 11, 33

Garber, C. B. 515
Goldschmidt, P. L. 257
Golinko, B. E. 1
Gorczynski, R. M. 593
Greenshaw, A. J. 615
Grigor, J. 127
Grof, E. 541, 687
Grof, P. 539, 541, 649, 687
Grota, L. 733
Grota, L. J. 475

Hakkou, F. 373
Hall, T. W. 657
Hamot, H. B. 293
Hamprecht, B. 481
Hariharasubramanian, N. 715
Herz, Le. 521
Herz, Lo. 521
Hiep, A. 109
Huff, F. J. 643
Hunt, G. E. 63

Ichikawa, K. 51, 285
Inoue, O. 385
Itil, K. Z. 397
Itil, T. M. 397
Itoh, H. 39, 51, 285
Iwamura, K. 51, 285

Jacobson, W. 621
Jahr, C. E. 503
Jancsàr, S. M. 263
Janicek, P. 547
Jessel, T. M. 503
Jeste, D. V. 277
Jhamandas, K. H. 565
Johnson, G. F. S. 63
Joshi, M. 733, 765

Kalin, N. H. 423, 459
Kamisada, M. 39
Kamishima, K. 39
Karoum, F. 153, 277
Kato, G. 71
Kaufmann, C. A. 277
Kelwala, S. 77
Kempf, E. 365
Kennedy, M. 593
Kiely, M. E. 691, 695
Kinemuchi, H. 385
Koga, Y. 39
Kwan, C.-Y. 665

Lader, M. 85
Lal, S. 691, 695, 779
Lane, J. 539, 687
Lapierre, Y. 661
LeGatt, D. F. 653
Leonard, B. E. 97, 263
Linnoila, M. 153
Livingstone, K. E. 635
Lockock, R. A. 701
Loo, P. 785

Maier, S. F. 435
Maire, J.-C. E. 637
Mandel, P. 365
Marriott, P. 109
Marshall, K. C. 515
Masuda, Y. 39
Mayer, D. J. 557
McKenzie, G. M. 757, 761
McQuade, P. 737
McQuade, P. S. 607, 705, 773, 789
Menon, G. N. 397
Micetich, R. G. 657
Mishra, R. K. 665
Miura, S. 39
Montalto, J. 11
Moroji, T. 419
Mosca, G. 411
Mosticyan, S. 711, 737
Murphy, M. G. 529, 719, 761

Nabeta, Y. 39
Nair, N. P. V. 711, 715, 737, 779, 789
Nakano, Y. 39
Nakatsu, K. 747
Nazarali, A. J. 657
Needler, M. C. 627
Niles, L. P. 475, 669
Norman, T. R. 115
Notelovitz, M. 11
Nyakas, C. 673

O'Conner, M. 127
Ogita, K. 39
Ohtsuka, N. 39
Orsatti, A. 411
Overstreet, D. H. 133

Pandey, G. N. 547
Pansa, M. 109
Patin, J. R. 293
Pert, A. 425
Peterson, M. R. 725
Phillis, J. W. 495
Pilapil, C. 715
Platt, J. E. 587
Poncelet, M. 373
Post, R. M. 425
Potter, W. Z. 153
Puglisi-Allegra, S. 365
Pulido, O. 475

Quirion, R. 571, 737

Rajakumar, G. 665
Rao, B. G. 719
Rihmer, Z. 649
Robertson, H. A. 725
Robinson, J. L. 769

Saint-Hilaire, J.-M. 635
Saitoh, F. 39
Sakurai, S. 39
Salt, J. S. 163
Satoh, K. 39
Savary, L. 257
Sawynok, J. 581, 729
Saxena, B. 687
Schlechter, M. D. 271, 359
Schleef, C. 365
Schousboe, A. 521
Schran, H. F. 277
Schwartz, G. 711, 737
Seggie, J. 733, 765
Shaw, C. 627
Silva, A. 411
Simeon, J. G. 683
Simon, P. 257, 373
Singer, G. 171
Singer, J. M. 293
Smith, D. F. 327
Stark-Adamec, C. 635
Stephens, D. A. 751
Stone, E. A. 587
Stratford, J. 691
Suranyi-Cadotte, B. 737
Suzuki, Y. 39
Szadoczky, E. 649
Szechtman, H. 743
Szerb, J. C. 761

Taberner, P. V. 163, 179
Tada, K. 419
Takamiya, M. 39
Tanoue, S. 39
Tasker, R. A. R. 747
Tateyama, M. 39, 51
Thavundayil, J. X. 695
Tominaga, T. 385

Torok-Both, G. 677
Trullas, R. 587
Tyrer, S. P. 751

Unwin, J. W. 179

Valzelli, L. 311
Vander Velden, P. L. 747

Wallace, M. 171
Walsh, A. 751
Warenycia, M. W. 757, 761
Warne, G. 11
Watenabe, N. 419
Weiss, S. R. B. 425
Werstuik, E. S. 733, 765
White, T. D. 487
Wilkinson, D. A. 621
Wilkinson, M. 621, 627
Williams, M. 209, 769
Wilson, W. H. 77
Wood, P. L. 705, 737, 773, 779, 785, 789
Wurtman, R. J. 637
Wyatt, R. J. 277

Yagi, G. 39, 51, 285
Yamasaki, T. 385
Yamazumi, S. 39
Yoshida, H. 39

Zacharko, R. M. 601
Zanussi, C. 411

SUBJECT INDEX

Acetylcholine
  striatal slices 640
  synthesis 137, 138, 638
  turnover rate and GABA in substantia nigra 790, 791
N-Acetylserotonin 475–9
  antiserum 476–8
  immunohistochemistry 477, 478
  target sites 478, 479
N-Acetyltransferase 476
ACTH 4–9 analog
  in attention deficit disorder 661–3
  dependent variables 663
Adenosine and benzodiazepine central actions 495
Adverse drug reactions
  amitriptyline 131
  citalopram 403
  dextroamphetamine 1–8
  haloperidol 57–9, 82
  lithium 68
  measurements 194
  methylphenidate 1–8
  neuroleptics 194
  thiothixine 82
  zimelidine 131
Affective disorders and lithium transport in red cells 547–54
Age, receptor number changes 630, 631
Aggression
  animal and human comparisons 317–19
  mouse strains and 5-HT levels 365–70
  muricidal
    anxiolytic effects 318
    mechanism 316
    serotonergic role 314–17
  pathological, conditions 315
  pathology 311–20
  social isolation in mice 367
Aging
  choline production 637–41
  cholinergic system 144
Alcohol
  behavioral effects in rat 271–5
    dose–response 273, 274
  preference in mice 179–82
    concentration 181
    fluid intake 182
  sleep times in mice 180
Alprazolam, cognitive tests on children 684, 686
Alzheimer's disease
  choline production 637–41
  cognitive defects 645, 646
  focal deficits 645
  language disorder 645
  memory disorder 644
  neuropsychological diagnosis 644, 645
  neuropsychology advances 643–7
γ-Aminobutyric acid (GABA) *see also* GABA, receptors
  –benzodiazepine/chloride ionophore complex 231–6
  benzodiazepine and 5-HT receptor interaction 35
  γ-vinyl and brain neurotransmitters 267
Amitriptyline
  in endogenous depression 127–31
    ratings 130
  side effects 131
Amotivational syndrome
  BPRS score 420
  and caerulein in marijuana user 419–21
AMP, cyclic
  determination 530, 531
  hormonal regulation in cell culture 482, 483
  neuroblastoma and membrane fatty acids 529–35
  prostaglandin-dependent accumulation 533
    inhibitor effects 534
Amphetamines
  exploratory behaviour in weanling rats 163–8
  locomotor activity in rats 249–53
    dose–response 251, 252
    time course 251, 253
  saw horse diagram 346
  stereopsychopharmacology 332
  striatal dynorphin levels 727
Analgesia
  brain electrical stimulation 557–62
    characteristics 558, 559
  opioid–neurotransmitter interactions 565–8
Animal models
  anxiolytic activity 163–8
  attachment bond 459–66
  depression 99–101, 435, 443, 444
    rodent separation 447–56
  evaluation guidelines 423
  muricidal aggression 314
Anomia, cognitive defects 645, 646
Anorexia, hyperactivity treatment 2, 3, 6
Antibody response, stress-induced immunosuppression 594, 595
Antidepressants
  brain amine uptake 317
  dopaminergic effects 104
  mode of action of specific 153–9
  pharmacology of new 97–105
Antinociception, GABAergic mechanisms 581–4
Antiparkinsonian drugs
  anticholinergic assessment 260
  comparisons 257–60
  dose–responses 259
  mouse motor activity 258
Anxiety
  receptor role 73
  WHO clinical assessment scale 193
Anxiolytics *see also* benzodiazepines
  classes 214–17
  molecular aspects of action 209–37
  muricidal aggression 318
  receptor-ligand interactions 235, 236
  structures 214, 215
Apomorphine
  penile tumescence 695–7

yawn timing and naloxone 743–6
Astrocytes
adenylyl cyclase activity and 5-HT 524
5-HT binding kinetics 523
ATP
dorsal horn subpopulations 503, 504
neuronal release 487–91
brain 488, 489
peripheral nervous system 489–91
Attachment bond disruption 459–66
hypothalamic-pituitary-adrenal function 463, 464
immune function 464, 465
metabolic effects 462, 463
monoamine system effects 465, 466
rhesus monkey 460, 461
sleep 462
Attention deficit disorder, ACTH 4–9 analog and methylphenidate 661–3

D-Baclofen
and L-baclofen and nociception 730
receptor interaction 729–31
Behavior
corticostriatal projection ablation 761–4
deficits 437–9
despair in mice and diphenylhydantoin 374, 375
exploratory and benzodiazepines 163–8
acute and chronic effects 166, 167
apparatus 165
passive avoidance and vasopressin 379–82
pharmacology and benzodiazepines 19–28
plasticity
habituation 134–6
learning and memory 136, 137
types 134
prevention 439, 440
Bemegride, chlordiazepoxide and amphetamine antagonism 362
Benzodiazepines
anxiolytic effects 27, 33–6
behavioral pharmacology 19–28
CNS actions 211
dependence 85–93
incidence 92
-inducing properties 86
dopamine metabolism 780
metabolite turnover 781
tolerance lack 781
drug abuse 86
exploration and locomotor activity 25
exploratory behavior in weanling rats 163–8
GABAergic nigrostriatal regulation 779–82
half-line 118
head dipping 26
hormonal effects 11–16
idiopathic hirsutism 11–16
metabolism 117
mode of action
adenosine role 495–9
scheme 234
molecular aspects of action 209–37
nitrobenzylthioinosine binding 497, 498
opiate interactions 213, 214
overdose 122, 123
plasma concentrations 123
pharmacokinetics 117–20
pharmacology 211–14
receptor affinities 33–6
serum levels, implications 115–23
anxiolytic response 120–2
methods 116
structures 212
tolerance 20, 21
recovery 24–7
withdrawal symptoms 88–91
Benztropine and erection 697
Brain
electrical stimulation and analgesia 557–62
applications 562
loci 559, 560
mechanisms 561, 562
neural circuits 560, 561
muscimol binding and melatonin 669–72
serotonergic projections 313
slices and receptor assay 622
Brief Psychiatric Rating Scale (BPRS) 278
and bromocriptine in schizophrenia 278–80
haloperidol response 285–92
serum levels 288, 289
Bromocriptine
low-dose in schizophrenics 277–82
plasma levels and BPRS 281
plasma levels and dose 281
Bupropion, cognitive tests in children 684, 685

Caerulein and marijuana use in amotivational syndrome 419–21
Cannabinoids, stereopsychopharmacology 336
Carbamazepine
amygdala kindling 428–30
cocaine-induced behavioral sensitization 427, 428
sensitization and kindling 425–32
β-Carbolines, benzodiazepine receptor antagonists 228
Cell culture
bradykinin effects 483
and neural function study 481–4
neuroblastoma NIE-115 529–35, 719–22
substance P effects 483, 484
taurin transport 484
Children, cognitive function and drugs 683–7
Chlordiazepoxide
behavioral effects 21–3
behavioral effects and antagonism 359–63
bemegride 362
dose–response 361
metabolites 24
plasma concentrations 24
Cholecystokinin (CCK)-octapeptide
BPRS score 712
in schizophrenia 711–13
Choline
brain slice superfusion 638, 639
production, Alzheimer's disease and aging 637–41
Cholinergic system
behavioral plasticity 133
drugs and tolerance 140
innominata-cortical pathway regulation 789–92

GABA and opioid effects 790
memory 143–5
stereopsychopharmacology 333, 334
Ciclindole
metabolites 774, 775
novel neuroleptic 773–6
receptor binding 774
Circadian rhythm and melatonin in depression 715–17
Citalopram
classification of doses 405
CNS effects 397–407
time-related 403
computer-analysed EEG classification 405
dose-related changes 402
drug discrimination 402
mode of action 401
safety 403
structure 399
Clinical assessment, biological psychiatry 190–4
Clorazepate, hormone effects 14
Clorgyline
depression 154–9
excretion 155, 156
C-4-methylamine production 390–2
C-14-N-methylphenylethanolamine 390–2
mood cycles 157
Cognitive function
drug effects in children 683–6
tests 684
Computer-analysed electroencephalogram 397–407
imipramine and citalopram 400
similarity coefficients of drugs 404
Corticostriatal projection, bilateral ablation and behavior 761–4
dexamphetamine response 762, 763
N-Cyanoethyltranylcypromine and brain 5-HT 657–60
Cyclohexane, chair conformation 348

Dementia, cholinergic system 144
Dependence
benzodiazepines 85–93
clinical 87
opioid-neurotransmitter interactions 565–8
Depression
animal models 99–101, 435, 443, 444
rodent separation 447–56
drug response prediction 649–52
imipramine binding marker 737–40
melatonin circadian rhythm 715–17
receptor role 72, 73
stressor-provoked behavioral disturbances 602, 603
WHO, clinical assessment scales 191–3
Desmethyldiazepam, hormonal correlations 15
Desmethylimipramine
footshock-induced anorexia 588
plasma corticosteroids 590
restraint-induced anorexia 589
stressor-provoked deficits antagonism 601–5
stress responses in rats 587–91
time course of effects 589
Dexamethasone suppression test 187–9
assessment 188
and depression indicator 187
drug response prediction 649–52
Dexamphetamine
bilateral corticostriatal projection ablation 762, 763
striatal response and parafascicular centromedian complex 757–60
behavior record 758, 759
lesions 759
Dextroamphetamine, side effects on hyperactivity 1–8
Diazepam
brain content and adenosine uptake 496, 497
hormonal effects 15
3,6-Dibutanoylmorphine, cataleptic potency 747–50
Digit symbol substitution test 91
Dihydro-β-erythroidine, nicotinic brain receptors 769–71
Diisopropyl fluorophosphate tolerance 141
Diphenylhydantoin
administration 373
behavior 374
behavioral despair 374, 376
mouse motor activity 374, 375
psychopharmacological profile 373–8
reserpine induced hypothermia 377
Diprenyl, monoamine metabolism 390–2
Discrimination training 360
Dopaminergic mechanisms
benzodiazepine effects 779–82
meta- and *para*-tyramine effects 705–8
stereopsychopharmacology 331, 332
Dorsal horn neurons, ATP excitation 503, 504
Drug discrimination 272
Drug-induced catalepsy 748
Drugs
classification and acquisition 174
response prediction 649–52
self-injection 171–7
Dynorphin, striatal and dopaminergic agents 725–8

Endorphin levels and opioid dependency 568
Epidemiology of tardive dyskinesia in Japan 39–48
Erection
assessment 696
dopamine mechanisms 695–9
placebo effect 697
Ethanol *see* alcohol
Extrapyramidal symptoms *see also* tardive dyskinesia
haloperidol serum levels 579

Flucindole 773–6
metabolites 774, 775
receptor binding 774
structure 776
Fluphenazine
rehospitalization 111
treatment intervals 40

GABA *see also* γ-aminobutyric acid, receptors
GABA agonists, antinociception 582–4
GABAergic mechanisms
antinociception 581–4
opiate antinociception 582
stereopsychopharmacology 335, 336

GABA transaminase inhibition
antinociception effects 584
neurotransmitter metabolism 265, 266
Glutamic acid decarboxylase activity *in vitro* 266
GMP, cyclic
CSF sequential samples 691–3
rostrocaudal gradient CSF 692, 693
Gonadotropin releasing hormone
gonadotropin response in schizophrenia 411–16
FSH 414
LH 414
prolactin 415, 416
testosterone 415, 416
stimulation 413
Growth hormone, insulin hypoglycaemia response and lithium 545
Growth suppression and hyperactivity treatment 5

Haloperidol
dose and diagnosis 79
evaluation 81
rapid tranquilization 77–83
schizophrenic types and response 287–90
hospitalization 290
serum level monitoring 51–61
clinical response 285–92
extrapyramidal symptoms 57–60
oral 56
preparations 55, 56
schedules 53–5
steady state timing 57
withdrawal 59, 60
striatal dynorphin levels 727
structure and flucindole 776
Hamilton anxiety ratings, benzodiazepine withdrawal 90
Hemicholinium-3, dose–response 140
Hirsutism, benzodiazepine effects 11–16
6-Hydroxydopamine lesions, and plasma corticosteroids 176
Hydroxyphenylacetic acid, *meta-* and *para-* metabolites 707
5-Hydroxytryptamine (5-HT, serotonin)
assessment 366
brain levels and *N*-cyanoethyltranylcypromine 657–60
brain levels, turnover and aggression 365–70
brain projections 313
cortex displacement 701–3
and MAO inhibitor 653–5
mechanism, stereopsychopharmacology 332, 333
metabolism and mouse strains 368
separation model levels 455
Hyperactivity treatment and side effects 1–8
Hyperexcitability
electrical stimulation and explants 509
calcium role 510
potassium role 511
hippocampal explants 507–12
Hypertensive rats, receptor changes 665–8

Imipramine binding, platelet-depression marker 737–40
Immune responses
associative learning effect 593
cyclophosphamide effects 597
rejection 595, 596
stress role 593–9
tumor growth modulation 597
Immunosuppression
conditioned 593
drug-induced 594, 595
Insomnia, hyperactivity treatment 2, 3, 6
Insulin sensitivity 687–90
dexamethasone effects 689, 690
lithium effects 688
nortriptyline effects 690
Interferon
features 353
opiate tolerance and dependence 351–4
hypotheses 352, 353
Isomers, diagram and structures 345

Japan, tardive dyskinesia prevalence 39–48

Kindling 507
amygdala 428–30
carbamazepine and lithium effects 425–32
hippocampal, naltrexone effects 673–6
model 426
technique 430

Learned helplessness
depression model 435–44
features 436
neurochemistry 440–2
pharmacology 440–2
Lithium
amygdala kindling 428–30
bioavailability 66, 667
cocaine-induced behavioral sensitization 426, 427
current interest and issues 539, 540
erythrocyte transport in affective disorders 547–54
in vitro correlations 549–41
Li^+–Na^+ exchange 553
measurements 548, 549
insulin sensitivity 688
and melatonin in pigmented eye rats 733–5
mood cycles 157
neuroendocrine effects 541–6
pharmacokinetics 63
pigmented eye rats 765–8
diet 766
metabolic effects 766, 767
plasma levels and excretion 64–6
ratio 549–51
response in aggressive mental handicap 751–4
sensitization and kindling effects 425–32
side effects 68
urinary excretion 67, 68
Locus coeruleus
culture, noradrenergic actions 515–19
glutamate effects 519
isolation 516
noradrenaline hyperpolarization 518

Marijuana and caerulin use 419–21
Melatonin
  circadian rhythm in depression 715–17
    normals 717
  and lithium in pigmented eye rats 733–5
  rat brain muscimol binding 669–72
    buffer effects 671
    triton effects 670
  serum levels and diet 735
Membrane fatty acids and linoleic acid levels 531, 532
Memory and cholinergic system 143–5
Mental handicap, lithium response in aggression 751–4
  assessment 752
  behavior 753
Mental health
  biological approaches 185, 186
  WHO information 200, 201
Methylphenidate
  attention deficit disorder 661–3
  side effects in hyperactivity 1–8
Methylphenylethanolamine, blood and brain distribution 390
Mianserin, pharmacological properties 101, 102
Mice, aggression and brain 5-HT 365–70
Monitoring, haloperidol serum levels 51–61
6-Monoacetylmorphine, cataleptic potency 747–50
Monoamine oxidase
  inhibitors and brain 5-HT 653–5
  in vitro assay 387
  in vivo measurement method 385–94
  C-14-methylamine production and inhibition 388, 389
  C-14-N-methylphenylethylamine inhibition 388, 389
  radiotracer 386

Naltrexone
  afterdischarge and behavioral depression 675, 676
  hippocampal kindled rats 673–6
Narcotic catalepsy 748, 749
Neuroleptics, novel 773–6
Neuronal ATP release
  central NS 488, 489
  peripheral NS 489, 490
Neurotransmitters and receptors 71–4
Nicotine, self-injection 173
  6-hydroxydopamine lesions 177
Nomifensine, pharmacological properties 102, 103
Noradrenergic mechanisms, stereopsychopharmacology 330, 331
Nortriptyline and insulin sensitivity 690

Olfactory bulbectomy, neurotransmitter changes 263–8
Opiates and stressed-induced analgesia 442, 443
Opioid mechanisms, stereopsychopharmacology 334, 335
Opioid peptides
  intrathecal analgesic action 574
  spinal cord distribution 572, 573

Pain *see also* analgesia
  spinal opioid receptors 571–5
Parafascicular centromedian lesions and dexamphetamine 758, 759
Pentobarbital, behavioral effects in rat 271–5
  bemegride 362
  dose–response 273, 274, 361
  specific antagonism 359–63
Pharmacokinetics
  benzodiazepines 117–20
  lithium preparations 63–9
Phenelzine
  body weights 681
  chronic effects in rat 677–81
  excretion rates 679
  expired 680
  organ weight effects 679
Phenylacetic acid
  assessment methods 610
  body fluid concentrations 610, 611
  drug effects on metabolism 611, 612
Phencyclidine and striatal dynorphin 727
Phenylcyclopropylamine isomers 347
Phenylethylamine
  assessment methods 608, 609
  aversive stimulus properties 618
  brain distribution and concentration 609, 610
  brain levels and N-cyanoethyltranylcypromine 659
  drug effects on metabolism 611, 612
  intracranial and self-stimulation 617, 618
  Newman projection of conformations 347
  reinforcement 615–18
  rewarding properties 616
  self-stimulation 616, 617
Phodopus sungorus, separation model of depression 447–56
  antidepressant treatment 449, 452, 453
  behavioral effects 450, 451
  body weights 450
  breeding colony 448, 449
  neurochemical changes 452–6
    and imipramine 454
Phospholipids
  catabolism in aging 639, 640
    causes 641
  choline sources 638, 639
Pigmented eye rats
  lithium effects 733–5, 765–8
  melatonin effects 733–5
Pilocarpine and operant response 142
Pineal gland, CGP-12177 binding 624
Piribedil and locomotor activity in rats 249–53
  dose–response 252
  time course 251, 253
Placebo, excretion rate 155
Platelets, imipramine binding in depression 738, 739
Procaine HC1, limbic system excitant 635
Prolactin, insulin hypoglycaemia and lithium 543, 544
Prostaglandins
  neuroblastoma production and fatty acids 529–35
    AMP accumulation 533
    release and linoleic acid supplement 532

synthesis inhibitors and AMP 534
Purkinje neurons
iontophoretic noradrenaline 517
noradrenergic actions in culture 515–19
ratemeter recording 517

Radiotracer method, metabolic trapping, monoamine oxidase 386
Rearing conditions, passive avoidance behavior 379–82
Receptors
age related changes 630, 631
examination, ligand use 628
expression, primary cell culture 521–5
laminar distribution pattern in cat 632, 633
and neurotransmitters 71–4
postnatal alterations 629
properties in cat critical period 627–33
quantification 621–5
Receptor, adrenergic
benzodiazepine affinities 36
benzodiazepine effects 33–6
cerebral cortex slices 623, 624
expression and culture 522
Receptor, baclofen 729–31
Receptor, benzodiazepine 217–22
antagonists 228–30, 233, 785–8
structures 228, 230
synthetic 229, 230
barbiturate interactions 224–6, 233
binding, anion effects 231
brain regions 219
butylbicyclophosphorothionate binding 787
complex, ligand effects 787
endogenous ligand 226, 227
GABA interactions 222–4, 230, 231, 233, 786
GABA shift concept 230, 231
inhibitory neurotransmitter action 217, 218
kidney type 221, 222
low affinity anticonvulsant 221
model 232
radioligand binding 218–20
subtypes 220, 221
Receptor, dopaminergic
agonist 349
antagonist 349
expression in cell culture 522, 523
hypertensive rat changes 665–8
Receptor, GABAergic agonist 350
Receptor, 5-hydroxytryptamine
benzodiazepine effects 33–6
GABA effects 35
biogenic amines inhibition 702, 703
changes in hypertensive rats 665–8
expression in cell culture 523
Receptor, muscarinic agonist 349
Receptors, nicotinic
agonist and antagonist regional binding 770
brain 769–71
radioligand binding pharmacology 771
Receptor, noradrenergic features 348
Receptor, opioid
hypothalamus slices 623
neuroblastoma cells 719–22
cholesterol effects 719, 720
enkephalin binding 720, 721
PGE_1-stimulated adenylate cyclase 721
scheme 350
spinal and pain 572–5
rostro-caudal distribution 574
subtypes 574
Reinforcement, β-phenylethylamine 615–18
Reserpine
-induced hypothermia 377
palpebral ptosis 377
Ro 5-4964 and adenosine accumulation 498, 499
Ro 15-1788
amphetamine and chlordiazepoxide antagonism 362
diazepam and adenosine uptake 498

Sandoz Clinical Assessment Geriatric (SCAG) Scale
comparable salient factor loadings 303
construct validity 293–305
dementia, sex and age 298
European versions 304
factor content 300, 301
factor loading matrix 298, 299
halo effects 304
scheme 295, 296
statistical analysis 297
validity 301
Schizophrenia
bromocriptine, low dose 277–82
cholecystokinin-octapeptide 711–13
gonadotropin releasing hormone response 411–16
haloperidol response and serum levels 285–92
hormone levels 413
lithium transport in red cells 552
neuroleptic intervals 111–13
receptor role 72
WHO, clinical assessment scales 191, 192
Self-injection of drugs 171–7
maintenance patterns 174, 175
Sensitization, carbamazepine and lithium effects 425–32
Separation *see Phodopus* sp., attachment bond
Serum levels
benzodiazepines 115–23
haloperidol 51–61
Smoking, benzodiazepine kinetics 120
Stereoisomers
chiral centre 347
diagrams 345
nomenclature systems 346, 347
psychotropic drug mixtures 342, 344
Stereopsychopharmacology 327–50
future uses 336
history 328, 329
nomenclature 329, 330
system effects 330–6
Stress
chronic 604
desmethylimipramine effects 587–91
brain stimulation 601–5
Stressed-induced analgesia 442, 443
Stressor-provoked deficits and desmethylimipramine 604, 605
Substantia innominata, regulatory inputs 791

Talsupram structure 399
Tardive dyskinesia

age 41
drug prescription 44, 45
environmental factors 43
hospitalization time 40–2
neuroleptic use 44, 46
prevalence, Japan 39–48
and sex 41, 42
Tetrahydrocarbazolamine neuroleptics 773–6
Thiothixine
dose and diagnosis 79
evaluation 81
rapid tranquilization 77–83
Tolerance
benzodiazepines 20, 21
anti-stress effects 27
anxiolytic effects 27, 28
recovery from 24–7
cholinergic drugs 140
diisopropyl fluorophosphate 141
opiate and interferon 351–4
opioid-neurotransmitter interactions 565–8
Tranquilization, rapid 77–83
Tranylcypromine and rat brain 5-HT 655
Trazodone, pharmacological properties 103
Treatment emergent symptoms, thiothixine and haloperidol 82
Tryptamine brain levels and *N*-cyanoethyltranylcypromine 659
Tryptophan hydroxylase, neurotransmitter metabolism 265, 266
Tumor growth and killer cell activity regulation 598
Tyramine
metabolites 706, 707
meta- and *para-* and dopamine system 705–8
Tyrosine, neurotransmitter metabolism 265, 266

arg-Vasopressin, passive avoidance and rearing 379–82

Weight loss, hyperactivity treatment 2–4
Withdrawal
benzodiazepine symptoms 88–91
opiates and interferon 351–4
Word-retrieval in Alzheimer's disease 646

Yawns
features 745
timing and apomorphine dose 743–6
and naloxone 744, 745

Zimelidine
endogenous depression 127–31
ratings 130
excretion 155, 156
pharmacological properties 104
side effects 131